Topic: infectious disease
GSK's ViiV said the CRL is related to chemistry manufacturing and controls, not the drug's safety profile.
In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.
Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.
Gilead Sciences recently committed $4.5 million in grants to transgender support and advocacy groups—$2.5 million more than it originally promised.
A new study showing that the flu can become resistant to Roche's Xofluza may affect efforts to get the drug approved in the U.S. to treat children.
Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.
Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.
Pardis Sabeti, co-founder, Sherlock Biosciences
Merck's antibiotic Recarbrio won its first FDA nod in July. Now, thanks to new trial results in severe pneumonia, it's eyeing another approval.
Gilead Sciences' new HIV funding effort looks to grant an initial $2 million to groups that help transgender people.